AUS
NZ
UK
CA
USA
IND
Highlights
Major ASX 200 names show elevated valuations compared to global and domestic peers
Commonwealth Bank, Wesfarmers, and Fisher & Paykel Healthcare analysed for valuation gaps
Cheaper comparables span international and local names with strong market positions
Within the financial sector, Commonwealth Bank of Australia (ASX:CBA) continues to command a premium valuation. As one of the highest-valued names on the ASX 200, the bank’s share price reflects a significant divergence from its book value, particularly when compared with other leading global banks.
In the UK, Lloyds Banking Group (LON:LLOY) operates with a structure and retail footprint bearing some resemblance to CBA’s market position. While Lloyds faces a different regulatory environment, it maintains a strong presence in the retail space with a cost-effective deposit base, offering a comparative scale dynamic.
Domestically, Westpac Banking Corporation (ASX:WBC) stands out as a more moderately priced alternative within Australia. Westpac maintains a similar strategic focus and capital strength, but trades at a valuation more closely aligned with industry norms.
Retail Divergence: Wesfarmers and its Global or Local Alternatives
In the retail segment, Wesfarmers Ltd (ASX:WES) is widely recognised for its strong business model, anchored by Bunnings Warehouse and supported by Kmart and Officeworks. However, its valuation has elevated substantially, placing it among the more expensive names in the consumer discretionary space.
Globally, Lowe’s Companies Inc (NYSE:LOW) offers a comparative example with a strong position in home improvement and similar economies of scale. The company’s scale enables pricing advantages and brand loyalty that mirror Bunnings’ Australian dominance.
Alternatively, Endeavour Group Ltd (ASX:EDV), with its retail liquor and hospitality business model, represents a local peer offering exposure to consumer behaviour with a structurally advantaged network. Endeavour’s competitive strength lies in its established retail channels and customer engagement in lifestyle-driven spending.
Medical Tech Premium: Fisher & Paykel Healthcare vs Philips and Siemens
In the healthcare equipment segment, Fisher & Paykel Healthcare Corp Ltd (ASX:FPH) remains a key player with a dominant position in respiratory care. The company benefits from proprietary technology and switching costs that help it maintain a leading market share in hospital-based applications.
Yet, the stock’s valuation has reached levels significantly above historical averages. In contrast, European giants like Koninklijke Philips NV (AMS:PHIA) and Siemens Healthineers AG (FRA:SHL) offer exposure to healthcare technologies and diagnostics, with market positions backed by established intellectual property and infrastructure.
These firms provide extensive product ecosystems and service integration, enabling recurring customer reliance and clinical continuity, all while trading at more restrained valuation levels compared to Fisher & Paykel.
Broader View on Valuation across ASX 200
Across sectors, several large-cap ASX stocks currently trade at elevated levels, potentially reflecting market confidence in stability and brand strength. However, as global and domestic peers demonstrate, alternative options may exist with similar quality attributes but more modest pricing.
For income-focused market participants, the relative dividend yield of local options such as Westpac or Endeavour may also align with broader portfolio objectives, with dividend yield playing a pivotal role in long-term returns.
